Thursday, October 2, 2008

Intradigm Gets $18.5M In Series B

Palo Alto-based Intradigm Corporation, which is developing systemic RNA interference (RNAi) therapeutics, said Thursday that it has raised $18.5M in a Series B financing. The round was led by Lilly Ventures, and included new investors Roche Venture Fund and MP Healthcare Venture Management. Prior investors Frazier Healthcare Ventures, Alta Partners, MediBic Alliance Technology Fund, and Novartis Venture Fund also invested in the round. Intradigm said the funding will go to advance its RNAi therapeutics platform. Bryan Dunnivant of Lilly Ventures joins the company's board along with the funding. More information »